SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 23, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                       Delaware                       52-1555759
               (State of Incorporation)             (I.R.S. Employer
                                                  Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


        Registrant's telephone number, including area code (301) 417-0770


                  No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.



<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 21, 1999:


FOR IMMEDIATE RELEASE
Contact:
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358

http://www.medimmune.com

MEDIMMUNE REPORTS 1999 FIRST HALF RESULTS

Gaithersburg, MD, July 21, 1999 -- MedImmune, Inc. (Nasdaq: MEDI) today reported
that total  revenues  in the first six months of 1999 were  $139.0  million,  an
increase of 66 percent compared with revenues of $83.9 million in the first half
of 1998.  Net earnings for the first half of 1999 were $18.5  million,  or $0.29
per share on a diluted basis,  compared to a loss of $5.4 million,  or $0.10 per
share,  in the first half of 1998. The increase in revenues in the first half of
1999 is primarily attributable to sales of Synagis (palivizumab),  the Company's
humanized  monoclonal  antibody  approved for the  prevention  of serious  lower
respiratory  tract  disease  caused  by  respiratory  syncytial  virus  (RSV) in
pediatric    patients    (please   see   full    prescribing    information   at
http://www.medimmune.com/products/synagispi.htm).

Product sales for second quarter included revenue from CytoGam  (Cytomegalovirus
Immune Globulin  Intravenous  (Human)) of $5.5 million,  revenue from Synagis of
$1.3 million and other product  sales of $1.4  million.  Product sales in second
quarter  of 1998  were $7.6  million  for  CytoGam  and $0.6  million  for other
products.  Other  revenues  for both  quarters  included  research  funding from
SmithKline  Beecham  (NYSE:SBH) for  MedImmune's  HPV vaccine program and second
quarter 1998 included a $15 million payment from Abbott Laboratories (NYSE: ABT)
received upon U.S. Food and Drug Administration (FDA) approval of Synagis.

Cost of sales was $4.6 million for second quarter 1999 compared to $14.5 million
in the 1998  quarter.  Cost of sales in second  quarter 1998 included a one-time
$10.5 million charge for certain  RespiGam  inventories  including raw materials
purchased prior to Synagis approval. Research and development spending increased
to $8.9 million in second  quarter 1999 from $7.3 million in second quarter 1998
primarily due to increased clinical spending for MEDI-507 and additional Synagis
trials.  Selling,  administrative and general expenses increased to $9.9 million
in second  quarter  of 1999 from $3.2  million in the 1998  quarter,  reflecting
overall  spending  increases in this area as well as  reimbursement in 1998 from
American  Home  Products  Corp.  (NYSE:AHP)  under  the  terms  of the  RespiGam
(Respiratory  Syncytial Virus Immune Globulin Intravenous (Human))  co-promotion
agreement.  Excluding  the effect of a one-time  charge of $10.3 million in June
1998 for buying  down  certain  Synagis  royalty  obligations,  other  operating
expenses  decreased to $6.0 million in second  quarter 1999 from $8.8 million in
1998.

The net loss in second quarter 1999 was $10.4 million or $0.19 per share on 56.0
million  shares  compared to a loss of $18.6  million or $0.35 per share on 53.1
million shares in second quarter 1998. Second quarter 1999 included a benefit of
$7.0 million for income  taxes;  no tax benefit was  recorded in second  quarter
1998.  Cash and  marketable  securities  at June 30,  1999 were  $184.2  million
compared to $134.9  million at December 31, 1998  reflecting  positive cash flow
from  operations.  Subsequent  to the quarter,  in early July 1999,  the Company
converted  its seven  percent  convertible  subordinated  notes into 6.1 million
shares of common  stock.  This had the  effect  of  reducing  long term debt and
increasing shareholders' equity by approximately $60 million.

"We continue to be very pleased with our  financial  results as well as with the
growth  and  development  of our  business,"  said  Wayne T.  Hockmeyer,  Ph.D.,
Chairman  and  Chief  Executive  Officer.  "Having  completed  one of  the  most
successful  biotech  product  launches  in the U.S.  ever  during  this past RSV
season,  this quarter our  attention and the attention of our partners at Abbott
Laboratories turned to the international  marketplace.  During second quarter we
received  a  positive  opinion  from  the  European  Committee  for  Proprietary
Medicinal  Products,  which we hope to translate into a marketing  authorization
for Europe later this year. We have now received approvals in nine countries and
filed for approval in 43. Also during the second quarter, our partners at Abbott
began a clinical  trial in Japan which we hope will put us in a position to file
for marketing approval in that market next year."

Dr. Hockmeyer added, "Progress continues in other areas of the business as well.
During the second  quarter,  our  manufacturing  and regulatory  groups achieved
another  milestone with the  submission of a supplement to our Biologic  License
Application  requesting  authorization  from the FDA to begin marketing  Synagis
produced at our manufacturing  facility in Frederick,  Maryland.  We are also on
track  to  submit  Investigational  New  Drug  Applications  to the FDA to begin
clinical trials with two new vaccines later this year."

Synagis is a humanized  monoclonal  antibody which was approved for marketing in
June 1998 by the U.S. Food and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of RSV disease.  Synagis is the first monoclonal antibody to be licensed for any
infectious disease.  Synagis is administered by intramuscular injection once per
month during anticipated periods of RSV prevalence in the community.  RSV is the
most common cause of pneumonia and bronchiolitis in infants and children. In the
Northern  Hemisphere,  the RSV season typically  commences in November and lasts
through April but it may begin earlier or persist later in certain communities.

CytoGam  is an  intravenous  immune  globulin  enriched  in  antibodies  against
cytomegalovirus  (CMV) and is marketed by MedImmune in the United States for the
prophylaxis against CMV disease associated with transplantation of kidney, lung,
liver, pancreas, and heart (please see full prescribing information attached and
at www.medimmune.com/products/cytopi1.htm).

RespiGam is an intravenous  immune globulin  enriched in antibodies  against RSV
and is marketed by MedImmune in the United States for the  prevention of serious
lower  respiratory  tract infection caused by RSV in children under 24 months of
age with  bronchopulmonary  dysplasia  (BPD) or a  history  of  premature  birth
(please    see    full     prescribing     information     attached    and    at
www.medimmune.com/products/resppi.htm).

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange  Commission.  The FDA is
currently reviewing a supplement to MedImmune's  Biologic License Application to
allow  production  of  Synagis  at  its  Frederick  manufacturing  facility.  No
assurance  can be given that the FDA will  approve the plant to supply  Synagis.
MedImmune  cautions that RSV disease occurs  primarily during the winter months;
the Company believes its operating results will reflect that seasonality for the
foreseeable future.

                                 -Table Follows-


<PAGE>

                                 MedImmune, Inc.
                   Selected Financial Information (Unaudited)
                      (in thousands, except per share data)
                       Condensed Statements of Operations
<TABLE>





<S>                                                                       <C>                        <C>
                                                  Three Months Ended June 30,  Six Months Ended June 30,
                                                  ---------------------------   ------------------------
                                                        1999        1998*        1999         1998*
                                                        ----        -----        ----         -----

Revenues:
  Product Sales                                     $   8,200    $   8,150    $ 135,196   $  51,043
  Other                                                 2,039       16,441        3,764      32,886
                                                    ---------    ---------    ---------   ---------
                                                       10,239       24,591      138,960      83,929
                                                    ---------    ---------    ---------   ---------

Costs and expenses:
  Cost of sales                                         4,554       14,483       35,821      36,758
  Research and development                              8,852        7,327       17,635      12,995
  Selling, admin. & gen                                 9,866        3,218       46,915      16,144
  Other operating expenses                              6,016       19,136       11,884      24,938
                                                    ---------    ---------    ---------   ---------
                                                       29,288       44,164      112,255      90,835
                                                    ---------    ---------    ---------   ---------
Interest income, net                                    1,671        1,005        2,930       1,543
                                                    ---------    ---------    ---------   ---------
(Loss) income before income tax                       (17,378)     (18,568)      29,635      (5,363)
(Benefit) provisionfor income taxes                    (7,017)          --       11,161          --
                                                    ---------    ---------    ---------   ---------
Net (loss) earnings                                 $ (10,361)   $ (18,568)   $  18,474   $  (5,363)
                                                    =========    =========    =========   =========
Basic (loss) earnings per share                     $   (0.19)   $   (0.35)   $     .33   $   (0.10)
                                                    =========    =========    =========   =========
Shares used in computing(loss) earnings per share      55,972       53,054       55,570      52,469
                                                    =========    =========    =========   =========
Diluted (loss) earnings per share                   $   (0.19)   $   (0.35)   $    0.29   $   (0.10)
                                                    =========    =========    =========   =========
Shares used in computing diluted (loss) earnings
 per share                                             55,972       53,054       65,682      52,469
                                                    =========    =========    =========   =========

MedImmune, Inc.
Condensed Balance Sheets                                                      June 30,      Dec. 31,
                                                                                1999          1998
                                                                             ---------      ---------

Assets:
   Cash and marketable securities                                             $184,232      $134,882
   Trade and contract receivables, net                                           2,274        34,837
   Inventory, net                                                               20,983        24,709
   Deferred taxes, net                                                          95,801        77,518
   Property and equipment, net                                                  77,265        74,822
   Other assets                                                                 15,281         6,352
                                                                              --------      --------
                                                                              $395,836      $353,120
                                                                              ========      ========

 Liabilities and shareholders' equity:
   Accounts payable                                                           $  2,072      $  4,052
   Accrued expenses                                                             20,954        33,397
   Long-term debt                                                               82,903        85,892
   Other liabilities                                                            17,286        19,947
   Shareholders' equity                                                        272,621       209,832
                                                                              --------      --------
                                                                              $395,836      $353,120
                                                                              ========      ========

Common shares outstanding                                                      56,626        54,655
                                                                              ========      ========

*Prior year share and per share  amounts  have been  restated to give effect for
 the 2 for 1 stock split on December 31, 1998.

                                       ###

</TABLE>


<PAGE>






(REGISTRANT)      MEDIMMUNE, INC.





BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 23, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE REPORTS 1999 FIRST HALF RESULTS", "secsgml_size_bytes": 15509}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99669232"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: July 23, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                       Delaware                       52-1555759
               (State of Incorporation)             (I.R.S. Employer
                                                  Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

        Registrant's telephone number, including area code (301) 417-0770

                  No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated July 21, 1999:

FOR IMMEDIATE RELEASE
Contact:
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358

http://www.medimmune.com

MEDIMMUNE REPORTS 1999 FIRST HALF RESULTS

Gaithersburg, MD, July 21, 1999 -- MedImmune, Inc. (Nasdaq: MEDI) today reported
that total  revenues  in the first six months of 1999 were  $139.0  million,  an
increase of 66 percent compared with revenues of $83.9 million in the first half
of 1998.  Net earnings for the first half of 1999 were $18.5  million,  or $0.29
per share on a diluted basis,  compared to a loss of $5.4 million,  or $0.10 per
share,  in the first half of 1998. The increase in revenues in the first half of
1999 is primarily attributable to sales of Synagis (palivizumab),  the Company's
humanized  monoclonal  antibody  approved for the  prevention  of serious  lower
respiratory  tract  disease  caused  by  respiratory  syncytial  virus  (RSV) in
pediatric    patients    (please   see   full    prescribing    information   at
http://www.medimmune.com/products/synagispi.htm).

Product sales for second quarter included revenue from CytoGam  (Cytomegalovirus
Immune Globulin  Intravenous  (Human)) of $5.5 million,  revenue from Synagis of
$1.3 million and other product  sales of $1.4  million.  Product sales in second
quarter  of 1998  were $7.6  million  for  CytoGam  and $0.6  million  for other
products.  Other  revenues  for both  quarters  included  research  funding from
SmithKline  Beecham  (NYSE:SBH) for  MedImmune's  HPV vaccine program and second
quarter 1998 included a $15 million payment from Abbott Laboratories (NYSE: ABT)
received upon U.S. Food and Drug Administration (FDA) approval of Synagis.

Cost of sales was $4.6 million for second quarter 1999 compared to $14.5 million
in the 1998  quarter.  Cost of sales in second  quarter 1998 included a one-time
$10.5 million charge for certain  RespiGam  inventories  including raw materials
purchased prior to Synagis approval. Research and development spending increased
to $8.9 million in second  quarter 1999 from $7.3 million in second quarter 1998
primarily due to increased clinical spending for MEDI-507 and additional Synagis
trials.  Selling,  administrative and general expenses increased to $9.9 million
in second  quarter  of 1999 from $3.2  million in the 1998  quarter,  reflecting
overall  spending  increases in this area as well as  reimbursement in 1998 from
American  Home  Products  Corp.  (NYSE:AHP)  under  the  terms  of the  RespiGam
(Respiratory  Syncytial Virus Immune Globulin Intravenous (Human))  co-promotion
agreement.  Excluding  the effect of a one-time  charge of $10.3 million in June
1998 for buying  down  certain  Synagis  royalty  obligations,  other  operating
expenses  decreased to $6.0 million in second  quarter 1999 from $8.8 million in
1998.

The net loss in second quarter 1999 was $10.4 million or $0.19 per share on 56.0
million  shares  compared to a loss of $18.6  million or $0.35 per share on 53.1
million shares in second quarter 1998. Second quarter 1999 included a benefit of
$7.0 million for income  taxes;  no tax benefit was  recorded in second  quarter
1998.  Cash and  marketable  securities  at June 30,  1999 were  $184.2  million
compared to $134.9  million at December 31, 1998  reflecting  positive cash flow
from  operations.  Subsequent  to the quarter,  in early July 1999,  the Company
converted  its seven  percent  convertible  subordinated  notes into 6.1 million
shares of common  stock.  This had the  effect  of  reducing  long term debt and
increasing shareholders' equity by approximately $60 million.

"We continue to be very pleased with our  financial  results as well as with the
growth  and  development  of our  business,"  said  Wayne T.  Hockmeyer,  Ph.D.,
Chairman  and  Chief  Executive  Officer.  "Having  completed  one of  the  most
successful  biotech  product  launches  in the U.S.  ever  during  this past RSV
season,  this quarter our  attention and the attention of our partners at Abbott
Laboratories turned to the international  marketplace.  During second quarter we
received  a  positive  opinion  from  the  European  Committee  for  Proprietary
Medicinal  Products,  which we hope to translate into a marketing  authorization
for Europe later this year. We have now received approvals in nine countries and
filed for approval in 43. Also during the second quarter, our partners at Abbott
began a clinical  trial in Japan which we hope will put us in a position to file
for marketing approval in that market next year."

Dr. Hockmeyer added, "Progress continues in other areas of the business as well.
During the second  quarter,  our  manufacturing  and regulatory  groups achieved
another  milestone with the  submission of a supplement to our Biologic  License
Application  requesting  authorization  from the FDA to begin marketing  Synagis
produced at our manufacturing  facility in Frederick,  Maryland.  We are also on
track  to  submit  Investigational  New  Drug  Applications  to the FDA to begin
clinical trials with two new vaccines later this year."

Synagis is a humanized  monoclonal  antibody which was approved for marketing in
June 1998 by the U.S. Food and Drug Administration for the prevention of serious
lower respiratory tract disease caused by RSV in pediatric patients at high risk
of RSV disease.  Synagis is the first monoclonal antibody to be licensed for any
infectious disease.  Synagis is administered by intramuscular injection once per
month during anticipated periods of RSV prevalence in the community.  RSV is the
most common cause of pneumonia and bronchiolitis in infants and children. In the
Northern  Hemisphere,  the RSV season typically  commences in November and lasts
through April but it may begin earlier or persist later in certain communities.

CytoGam  is an  intravenous  immune  globulin  enriched  in  antibodies  against
cytomegalovirus  (CMV) and is marketed by MedImmune in the United States for the
prophylaxis against CMV disease associated with transplantation of kidney, lung,
liver, pancreas, and heart (please see full prescribing information attached and
at www.medimmune.com/products/cytopi1.htm).

RespiGam is an intravenous  immune globulin  enriched in antibodies  against RSV
and is marketed by MedImmune in the United States for the  prevention of serious
lower  respiratory  tract infection caused by RSV in children under 24 months of
age with  bronchopulmonary  dysplasia  (BPD) or a  history  of  premature  birth
(please    see    full     prescribing     information     attached    and    at
www.medimmune.com/products/resppi.htm).

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange  Commission.  The FDA is
currently reviewing a supplement to MedImmune's  Biologic License Application to
allow  production  of  Synagis  at  its  Frederick  manufacturing  facility.  No
assurance  can be given that the FDA will  approve the plant to supply  Synagis.
MedImmune  cautions that RSV disease occurs  primarily during the winter months;
the Company believes its operating results will reflect that seasonality for the
foreseeable future.

                                 -Table Follows-
MedImmune, Inc.
                   Selected Financial Information (Unaudited)
                      (in thousands, except per share data)
                       Condensed Statements of Operations
Three Months Ended June 30,  Six Months Ended June 30,
                                                  ---------------------------   ------------------------
                                                        1999        1998*        1999         1998*
                                                        ----        -----        ----         -----

Revenues:
  Product Sales                                     $   8,200    $   8,150    $ 135,196   $  51,043
  Other                                                 2,039       16,441        3,764      32,886
                                                    ---------    ---------    ---------   ---------
                                                       10,239       24,591      138,960      83,929
                                                    ---------    ---------    ---------   ---------

Costs and expenses:
  Cost of sales                                         4,554       14,483       35,821      36,758
  Research and development                              8,852        7,327       17,635      12,995
  Selling, admin. & gen                                 9,866        3,218       46,915      16,144
  Other operating expenses                              6,016       19,136       11,884      24,938
                                                    ---------    ---------    ---------   ---------
                                                       29,288       44,164      112,255      90,835
                                                    ---------    ---------    ---------   ---------
Interest income, net                                    1,671        1,005        2,930       1,543
                                                    ---------    ---------    ---------   ---------
(Loss) income before income tax                       (17,378)     (18,568)      29,635      (5,363)
(Benefit) provisionfor income taxes                    (7,017)          --       11,161          --
                                                    ---------    ---------    ---------   ---------
Net (loss) earnings                                 $ (10,361)   $ (18,568)   $  18,474   $  (5,363)
                                                    =========    =========    =========   =========
Basic (loss) earnings per share                     $   (0.19)   $   (0.35)   $     .33   $   (0.10)
                                                    =========    =========    =========   =========
Shares used in computing(loss) earnings per share      55,972       53,054       55,570      52,469
                                                    =========    =========    =========   =========
Diluted (loss) earnings per share                   $   (0.19)   $   (0.35)   $    0.29   $   (0.10)
                                                    =========    =========    =========   =========
Shares used in computing diluted (loss) earnings
 per share                                             55,972       53,054       65,682      52,469
                                                    =========    =========    =========   =========

MedImmune, Inc.
Condensed Balance Sheets                                                      June 30,      Dec. 31,
                                                                                1999          1998
                                                                             ---------      ---------

Assets:
   Cash and marketable securities                                             $184,232      $134,882
   Trade and contract receivables, net                                           2,274        34,837
   Inventory, net                                                               20,983        24,709
   Deferred taxes, net                                                          95,801        77,518
   Property and equipment, net                                                  77,265        74,822
   Other assets                                                                 15,281         6,352
                                                                              --------      --------
                                                                              $395,836      $353,120
                                                                              ========      ========

 Liabilities and shareholders' equity:
   Accounts payable                                                           $  2,072      $  4,052
   Accrued expenses                                                             20,954        33,397
   Long-term debt                                                               82,903        85,892
   Other liabilities                                                            17,286        19,947
   Shareholders' equity                                                        272,621       209,832
                                                                              --------      --------
                                                                              $395,836      $353,120
                                                                              ========      ========

Common shares outstanding                                                      56,626        54,655
                                                                              ========      ========

*Prior year share and per share  amounts  have been  restated to give effect for
 the 2 for 1 stock split on December 31, 1998.

                                       ###
(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            July 23, 1999